<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464737</url>
  </required_header>
  <id_info>
    <org_study_id>SP888</org_study_id>
    <nct_id>NCT00464737</nct_id>
  </id_info>
  <brief_title>The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.</brief_title>
  <acronym>SP888</acronym>
  <official_title>A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Doses of Rotigotine in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to investigate the efficacy and safety of rotigotine as compared to placebo in
      reducing signs and symptoms of fibromyalgia syndrome. The effects of rotigotine on pain,
      sleep, general activity, mood, and quality of life, and the use of rescue medication to treat
      pain will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall post-Baseline duration of treatment was 13 weeks. The trial consisted of a 4-week
      Titration Phase, an 8-week Maintenance Phase, a 1-week De-escalation Phase, and a 2-week
      Safety Follow-Up Phase. If subjects met the eligibility criteria, they were randomized to
      receive rotigotine 4 mg/24 hrs, rotigotine 8 mg/24 hrs, or placebo during the Maintenance
      Phase. During the 4-week Titration Phase, subjects assigned to rotigotine were titrated at
      weekly intervals of 2 mg/24 hrs until they reached 4 mg/24 hrs or 8 mg/24 hrs. All subjects
      who completed the 4-week Titration Phase entered an 8-week Maintenance Phase and were
      maintained at their randomized dose (rotigotine 4 mg/24 hrs, rotigotine 8 mg/24 hrs, or
      placebo). No dose adjustment was allowed during the Maintenance Phase. The Treatment Phase
      was defined as the combined Titration and Maintenance Phases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)</measure>
    <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
    <description>The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)</measure>
    <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
    <description>The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
    <description>The Fibromyalgia Impact Questionnaire (FIQ) Total Score ranges from 0 to 100 with higher scores corresponding to a greater impact of fibromyalgia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Myalgic Score to the Last Assessment in the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
    <description>Total Myalgic Score ranges from 0 to 54 with higher scores corresponding to a greater level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
    <description>Sleep scale - the subject rated quality of sleep, from 0 (very good sleep) to 10 (very poor sleep)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
    <description>General activity scale - the subject rated how the pain had interfered with general activity, from 0 (did not interfere) to 10 (completely interfered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) Assessment From Baseline to the Last Assessment in the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
    <description>The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning and Evening Pain Scores to the Last 2 Weeks of the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
    <description>An 11-point Likert scale was used for subjects to assess pain, from 0 (no pain) to 10 (worst pain ever experienced).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Using Rescue Medication and Alcohol During the 12-week Treatment Phase</measure>
    <time_frame>12-week Treatment Phase</time_frame>
    <description>Subjects recorded use of rescue medication for pain in the diary daily in the evening with a Yes/No response. Use of alcohol to treat pain in the past 24 hours was recorded with a Yes/No response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12</measure>
    <time_frame>End of the Maintenance Phase/Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores to the Last Assessment in the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS) is a self-administered instrument for detecting anxiety and depression in medical outpatients. Scores range from 0 to 21 for each subscale with higher scores reflecting a greater level of anxiety or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fibromyalgia Symptom Scores to the Last Assessment in the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
    <description>All scores range from 0 to 10 with higher scores corresponding to a greater level of symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Beck Depression Inventory-II (BDI-II) Scores to the Last Assessment in the 12-week Treatment Phase</measure>
    <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
    <description>The Beck Depression Inventory-II is a 21-item questionnaire. Each item is scored on a scale of 0 to 3 with a total score ranging from 0 to 63. A higher total score is associated with more severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Presence of Impulse Control Disorders</measure>
    <time_frame>12-week Treatment Phase</time_frame>
    <description>Impulse control disorders (ICDs) are a set of psychiatric disorders in which a person is unable to control strong and often harmful impulses. They are assessed in this study using the Jay Modified Minnesota Impulsive Disorders Interview (Jay Modified MIDI), which focuses on the five most common ICDs that may be associated with dopamine agonist use: compulsive buying, compulsive gambling, compulsive eating, hypersexuality and punding (performing repetitive and/or mechanical tasks).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Fibromyalgia Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotigotine 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg/24 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotigotine 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/24 hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine</intervention_name>
    <description>Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)</description>
    <arm_group_label>Rotigotine 4 mg</arm_group_label>
    <other_name>Neupro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine</intervention_name>
    <description>Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)</description>
    <arm_group_label>Rotigotine 8 mg</arm_group_label>
    <other_name>Neupro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female, 18 to 65 years of age (inclusive)

          -  Subject fulfills all 3 points of the American College of Rheumatology (ACR) definition
             for diagnosis of fibromyalgia (pain, stiffness, and/or sleep disorder)

          -  Subject must complete an adequate washout period for excluded medications, as
             necessary, prior to beginning the Baseline Diary Phase

          -  Subject has at least moderate pain that is defined as an average pain intensity of ≥5
             on an 11-point Likert pain scale (0-10) during the 7 days prior to Baseline

          -  Subject must have at least 5 morning and 5 evening Likert pain scale scores for the 7
             days immediately prior to Visit 2 and the average daily pain score over these 7 days
             must be ≥5 (average daily pain score is determined as follows: calculate the mean of
             the morning and evening scores separately using all pain scores for the 7 days
             immediately prior to Visit 2; add the mean morning and evening scores and divide by 2)

          -  Subject has a score of ≥50 on Fibromyalgia Impact Questionnaire (FIQ), with a score of
             100 representing severe disease at Baseline

        Exclusion Criteria:

          -  Subject has symptomatic regional or structural rheumatic disease (eg, knee or hip
             osteoarthritis, bursitis, tendonitis), rheumatic autoimmune disease or inflammatory
             rheumatic disease, such as systemic lupus erythematosus (SLE), mild primary
             osteoarthritis of the hand(s) is allowed

          -  Subject has diagnosed neuropathic pain syndrome

          -  Subject has received therapy with a dopamine agonist (eg, pramipexole, ropinirole) for
             3 months or longer that was not considered effective in managing fibromyalgia symptoms

          -  Subject is receiving disability or is involved in litigation related to fibromyalgia
             syndrome

          -  Subject has significant psychopathology as determined by the investigator based on
             results of the Structural Clinical Interview for DSM-IV Diagnosis (SCID-I). The SCID-I
             must be administered by a physician or clinical psychologist trained to administer the
             instrument

          -  Subject has evidence of an impulse control disorder according to the Jay Modified
             Minnesota Impulsive Disorders Interview (MIDI)

          -  Subject has any medical condition that, in the opinion of the investigator, could
             jeopardize or compromise the subject's ability to participate in this trial

          -  Subject has orthostatic hypotension with a decrease of blood pressure (BP) from supine
             to standing position of ≥20 mmHg in systolic blood pressure (SBP) or of ≥10 mmHg in
             diastolic blood pressure (DBP) taken from the 5-minute supine value and the 1- and/or
             3-minute standing measurements, or supine SBP &lt;105 mmHg at Baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Souderton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crossville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>For Safety Alerts amd Recalls refer to</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <results_first_submitted>November 23, 2009</results_first_submitted>
  <results_first_submitted_qc>November 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2010</results_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibromyalgia Syndrome</keyword>
  <keyword>Rotigotine</keyword>
  <keyword>Neupro</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Full Analysis Set (FAS) contains all randomized subjects who received at least 1 dose of trial medication, and had at least 1 post-Baseline Likert pain score. The Per Protocol Set contains all subjects in the FAS who completed at least 2 weeks of the Maintenance Phase and had no major protocol deviations.</recruitment_details>
      <pre_assignment_details>Participant flow is based on the 230 randomized subjects however 1 subject randomized to Rotigotine 4 mg/24 hrs did not receive study medication and was excluded from the Safety Set. Thus 229 subjects are included in summaries of baseline characteristics and adverse events. The excluded subject was a 47-year old female enrolled in the United States</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>Rotigotine 4 mg</title>
          <description>Rotigotine 4 mg/24 hrs</description>
        </group>
        <group group_id="P3">
          <title>Rotigotine 8 mg</title>
          <description>Rotigotine 8 mg/24 hrs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Subject's schedule doesn't permit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Subject left town; family illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Study demands too great</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Personal family reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Subject's disability per sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>Rotigotine 4 mg</title>
          <description>Rotigotine 4 mg/24 hrs</description>
        </group>
        <group group_id="B3">
          <title>Rotigotine 8 mg</title>
          <description>Rotigotine 8 mg/24 hrs</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="10.7"/>
                    <measurement group_id="B2" value="47.5" spread="10.3"/>
                    <measurement group_id="B3" value="47.0" spread="11.6"/>
                    <measurement group_id="B4" value="47.0" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)</title>
        <description>The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).</description>
        <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
        <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)</title>
          <description>The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).</description>
          <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="1.83"/>
                    <measurement group_id="O2" value="-1.27" spread="1.86"/>
                    <measurement group_id="O3" value="-0.83" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase</title>
        <description>The Fibromyalgia Impact Questionnaire (FIQ) Total Score ranges from 0 to 100 with higher scores corresponding to a greater impact of fibromyalgia</description>
        <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
        <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 80, 64 and 63 patients respectively are included in this summary based on the Full Analysis Set and have the Last Assessment in the 12-week Treatment Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase</title>
          <description>The Fibromyalgia Impact Questionnaire (FIQ) Total Score ranges from 0 to 100 with higher scores corresponding to a greater impact of fibromyalgia</description>
          <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 80, 64 and 63 patients respectively are included in this summary based on the Full Analysis Set and have the Last Assessment in the 12-week Treatment Phase.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="15.6"/>
                    <measurement group_id="O2" value="-13.4" spread="13.7"/>
                    <measurement group_id="O3" value="-12.8" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Myalgic Score to the Last Assessment in the 12-week Treatment Phase</title>
        <description>Total Myalgic Score ranges from 0 to 54 with higher scores corresponding to a greater level of pain.</description>
        <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
        <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Myalgic Score to the Last Assessment in the 12-week Treatment Phase</title>
          <description>Total Myalgic Score ranges from 0 to 54 with higher scores corresponding to a greater level of pain.</description>
          <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase</title>
        <description>Sleep scale - the subject rated quality of sleep, from 0 (very good sleep) to 10 (very poor sleep)</description>
        <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
        <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase</title>
          <description>Sleep scale - the subject rated quality of sleep, from 0 (very good sleep) to 10 (very poor sleep)</description>
          <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="2.01"/>
                    <measurement group_id="O2" value="-0.82" spread="2.03"/>
                    <measurement group_id="O3" value="-0.48" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase</title>
        <description>General activity scale - the subject rated how the pain had interfered with general activity, from 0 (did not interfere) to 10 (completely interfered)</description>
        <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
        <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase</title>
          <description>General activity scale - the subject rated how the pain had interfered with general activity, from 0 (did not interfere) to 10 (completely interfered)</description>
          <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="2.05"/>
                    <measurement group_id="O2" value="-1.19" spread="1.82"/>
                    <measurement group_id="O3" value="-0.88" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGIC) Assessment From Baseline to the Last Assessment in the 12-week Treatment Phase</title>
        <description>The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).</description>
        <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
        <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 76, 58, and 51 patients respectively are included in this summary based on the Full Analysis Set and have the Last Assessment in the 12-week Treatment Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change (PGIC) Assessment From Baseline to the Last Assessment in the 12-week Treatment Phase</title>
          <description>The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).</description>
          <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 76, 58, and 51 patients respectively are included in this summary based on the Full Analysis Set and have the Last Assessment in the 12-week Treatment Phase.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mildly better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mildly worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning and Evening Pain Scores to the Last 2 Weeks of the 12-week Treatment Phase</title>
        <description>An 11-point Likert scale was used for subjects to assess pain, from 0 (no pain) to 10 (worst pain ever experienced).</description>
        <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
        <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning and Evening Pain Scores to the Last 2 Weeks of the 12-week Treatment Phase</title>
          <description>An 11-point Likert scale was used for subjects to assess pain, from 0 (no pain) to 10 (worst pain ever experienced).</description>
          <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 81, 70 and 72 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Full Analysis Set.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning Pain Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="1.91"/>
                    <measurement group_id="O2" value="-1.30" spread="1.91"/>
                    <measurement group_id="O3" value="-0.78" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening Pain Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="1.82"/>
                    <measurement group_id="O2" value="-1.24" spread="1.90"/>
                    <measurement group_id="O3" value="-0.88" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Using Rescue Medication and Alcohol During the 12-week Treatment Phase</title>
        <description>Subjects recorded use of rescue medication for pain in the diary daily in the evening with a Yes/No response. Use of alcohol to treat pain in the past 24 hours was recorded with a Yes/No response.</description>
        <time_frame>12-week Treatment Phase</time_frame>
        <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Using Rescue Medication and Alcohol During the 12-week Treatment Phase</title>
          <description>Subjects recorded use of rescue medication for pain in the diary daily in the evening with a Yes/No response. Use of alcohol to treat pain in the past 24 hours was recorded with a Yes/No response.</description>
          <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12</title>
        <time_frame>End of the Maintenance Phase/Week 12</time_frame>
        <population>The number of patients in the Placebo group has been presented as 0 as this outcome measure is not applicable for this treatment group. Of the 73 (Rotigotine 4 mg) and 74 (Rotigotine 8 mg) patients respectively in the Safety Set, a total of 41 and 20 patients respectively at the end of Maintenance Phase/Week 12 have this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12</title>
          <population>The number of patients in the Placebo group has been presented as 0 as this outcome measure is not applicable for this treatment group. Of the 73 (Rotigotine 4 mg) and 74 (Rotigotine 8 mg) patients respectively in the Safety Set, a total of 41 and 20 patients respectively at the end of Maintenance Phase/Week 12 have this assessment.</population>
          <units>ug/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2388" spread="0.2337"/>
                    <measurement group_id="O3" value="0.2981" spread="0.2973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores to the Last Assessment in the 12-week Treatment Phase</title>
        <description>The Hospital Anxiety and Depression Scale (HADS) is a self-administered instrument for detecting anxiety and depression in medical outpatients. Scores range from 0 to 21 for each subscale with higher scores reflecting a greater level of anxiety or depression.</description>
        <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
        <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores to the Last Assessment in the 12-week Treatment Phase</title>
          <description>The Hospital Anxiety and Depression Scale (HADS) is a self-administered instrument for detecting anxiety and depression in medical outpatients. Scores range from 0 to 21 for each subscale with higher scores reflecting a greater level of anxiety or depression.</description>
          <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fibromyalgia Symptom Scores to the Last Assessment in the 12-week Treatment Phase</title>
        <description>All scores range from 0 to 10 with higher scores corresponding to a greater level of symptom severity.</description>
        <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
        <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibromyalgia Symptom Scores to the Last Assessment in the 12-week Treatment Phase</title>
          <description>All scores range from 0 to 10 with higher scores corresponding to a greater level of symptom severity.</description>
          <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Beck Depression Inventory-II (BDI-II) Scores to the Last Assessment in the 12-week Treatment Phase</title>
        <description>The Beck Depression Inventory-II is a 21-item questionnaire. Each item is scored on a scale of 0 to 3 with a total score ranging from 0 to 63. A higher total score is associated with more severe depressive symptoms.</description>
        <time_frame>Baseline, Last assessment in the 12-week Treatment Phase</time_frame>
        <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Beck Depression Inventory-II (BDI-II) Scores to the Last Assessment in the 12-week Treatment Phase</title>
          <description>The Beck Depression Inventory-II is a 21-item questionnaire. Each item is scored on a scale of 0 to 3 with a total score ranging from 0 to 63. A higher total score is associated with more severe depressive symptoms.</description>
          <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Presence of Impulse Control Disorders</title>
        <description>Impulse control disorders (ICDs) are a set of psychiatric disorders in which a person is unable to control strong and often harmful impulses. They are assessed in this study using the Jay Modified Minnesota Impulsive Disorders Interview (Jay Modified MIDI), which focuses on the five most common ICDs that may be associated with dopamine agonist use: compulsive buying, compulsive gambling, compulsive eating, hypersexuality and punding (performing repetitive and/or mechanical tasks).</description>
        <time_frame>12-week Treatment Phase</time_frame>
        <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Presence of Impulse Control Disorders</title>
          <description>Impulse control disorders (ICDs) are a set of psychiatric disorders in which a person is unable to control strong and often harmful impulses. They are assessed in this study using the Jay Modified Minnesota Impulsive Disorders Interview (Jay Modified MIDI), which focuses on the five most common ICDs that may be associated with dopamine agonist use: compulsive buying, compulsive gambling, compulsive eating, hypersexuality and punding (performing repetitive and/or mechanical tasks).</description>
          <population>Based on the observed outcome for the primary efficacy variable for this study, an abbreviated clinical study report was produced. Summaries were not produced for all pre-planned outcome measures and thus these results are not available. This summary was not produced for the abbreviated clinical study report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)</title>
        <description>The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).</description>
        <time_frame>Baseline, Last 2 weeks of the 12-week Treatment Phase</time_frame>
        <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 50, 33 and 22 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Per Protocol Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Rotigotine 4 mg</title>
            <description>Rotigotine 4 mg/24 hrs</description>
          </group>
          <group group_id="O3">
            <title>Rotigotine 8 mg</title>
            <description>Rotigotine 8 mg/24 hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)</title>
          <description>The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).</description>
          <population>Of the 82 (Placebo), 74 (Rotigotine 4 mg), and 74 (Rotigotine 8 mg) patients randomized, 50, 33 and 22 patients respectively are included in the summary of the last 2 weeks of the 12-week Treatment Phase, based on the Per Protocol Set.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.79"/>
                    <measurement group_id="O2" value="-2.09" spread="2.07"/>
                    <measurement group_id="O3" value="-1.57" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Set (SS) is comprised of all subjects who received at least 1 dose of trial medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Rotigotine 4 mg</title>
          <description>Rotigotine 4 mg/24 hrs</description>
        </group>
        <group group_id="E3">
          <title>Rotigotine 8 mg</title>
          <description>Rotigotine 8 mg/24 hrs</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Lung injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="82"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="73"/>
                <counts group_id="E3" events="63" subjects_affected="48" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 days but &lt;= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

